| Michael M Einstein, MD | |
|
85 Seymour St, Suite 1000, Hartford, CT 06106-5501 | |
| (860) 246-2571 | |
| (860) 246-3691 |
| Full Name | Michael M Einstein |
|---|---|
| Gender | Male |
| Speciality | Gastroenterology |
| Experience | 21 Years |
| Location | 85 Seymour St, Hartford, Connecticut |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1659339901 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RG0100X | Internal Medicine - Gastroenterology | 49700 (Connecticut) | Primary |
| 207RT0003X | Internal Medicine - Transplant Hepatology | 49700 (Connecticut) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Hartford Hospital | Hartford, CT | Hospital |
| Day Kimball Hospital | Putnam, CT | Hospital |
| Bristol Hospital | Bristol, CT | Hospital |
| Windham Community Memorial Hospital | Willimantic, CT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Hartford Hospital | 2567366016 | 827 |
| Connecticut Gi Pc | 9830110758 | 185 |
News Archive
DiagnoCure Inc. (TSX: CUR) announced that Gen-Probe, Inc. (NASDAQ: GPRO), its partner for the development and commercialization of the PCA3 prostate cancer test, has confirmed today the beginning of a U.S. clinical study intended to secure U.S. regulatory approval of the PROGENSA(R) PCA3 assay, a new molecular test that may help determine the need for a repeat prostate biopsy.
Kaiser Permanente, one of America's leading health care providers and not-for-profit health plans, has been named one of INROADS' Top 10 Corporate Sponsors. The nation's largest non-profit source of salaried corporate internships, INROADS, Inc. develops diverse, skilled talent to become Corporate America's future business, science, technology, engineering and math (STEM) leaders.
The President and CEO of Three Rivers Pharmaceuticals, Donald J. Kerrish, RPh., stated, "The approval of Ribasphere™ marks a milestone in the treatment of HCV. Ribasphere™ is positioned to break down the economic barriers that have existed for the past decade in treating this chronic and potentially deadly disease." Traditionally the cost of treatment for HCV can range from $20,000 – $25,000 annually. "Our aim is to bring affordable medicine to all individuals infected with this dreadful disease." Mr. Kerrish continued.
New research findings may help scientists design drugs to treat a virus infection that causes potentially fatal brain swelling and paralysis in children.
› Verified 4 days ago
| Entity Name | Hartford Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1407806391 PECOS PAC ID: 2567366016 Enrollment ID: O20031125000700 |
News Archive
DiagnoCure Inc. (TSX: CUR) announced that Gen-Probe, Inc. (NASDAQ: GPRO), its partner for the development and commercialization of the PCA3 prostate cancer test, has confirmed today the beginning of a U.S. clinical study intended to secure U.S. regulatory approval of the PROGENSA(R) PCA3 assay, a new molecular test that may help determine the need for a repeat prostate biopsy.
Kaiser Permanente, one of America's leading health care providers and not-for-profit health plans, has been named one of INROADS' Top 10 Corporate Sponsors. The nation's largest non-profit source of salaried corporate internships, INROADS, Inc. develops diverse, skilled talent to become Corporate America's future business, science, technology, engineering and math (STEM) leaders.
The President and CEO of Three Rivers Pharmaceuticals, Donald J. Kerrish, RPh., stated, "The approval of Ribasphere™ marks a milestone in the treatment of HCV. Ribasphere™ is positioned to break down the economic barriers that have existed for the past decade in treating this chronic and potentially deadly disease." Traditionally the cost of treatment for HCV can range from $20,000 – $25,000 annually. "Our aim is to bring affordable medicine to all individuals infected with this dreadful disease." Mr. Kerrish continued.
New research findings may help scientists design drugs to treat a virus infection that causes potentially fatal brain swelling and paralysis in children.
› Verified 4 days ago
| Entity Name | Hartford Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1770696643 PECOS PAC ID: 2567366016 Enrollment ID: O20031125000752 |
News Archive
DiagnoCure Inc. (TSX: CUR) announced that Gen-Probe, Inc. (NASDAQ: GPRO), its partner for the development and commercialization of the PCA3 prostate cancer test, has confirmed today the beginning of a U.S. clinical study intended to secure U.S. regulatory approval of the PROGENSA(R) PCA3 assay, a new molecular test that may help determine the need for a repeat prostate biopsy.
Kaiser Permanente, one of America's leading health care providers and not-for-profit health plans, has been named one of INROADS' Top 10 Corporate Sponsors. The nation's largest non-profit source of salaried corporate internships, INROADS, Inc. develops diverse, skilled talent to become Corporate America's future business, science, technology, engineering and math (STEM) leaders.
The President and CEO of Three Rivers Pharmaceuticals, Donald J. Kerrish, RPh., stated, "The approval of Ribasphere™ marks a milestone in the treatment of HCV. Ribasphere™ is positioned to break down the economic barriers that have existed for the past decade in treating this chronic and potentially deadly disease." Traditionally the cost of treatment for HCV can range from $20,000 – $25,000 annually. "Our aim is to bring affordable medicine to all individuals infected with this dreadful disease." Mr. Kerrish continued.
New research findings may help scientists design drugs to treat a virus infection that causes potentially fatal brain swelling and paralysis in children.
› Verified 4 days ago
| Entity Name | Connecticut Gi Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023124625 PECOS PAC ID: 9830110758 Enrollment ID: O20070112000011 |
News Archive
DiagnoCure Inc. (TSX: CUR) announced that Gen-Probe, Inc. (NASDAQ: GPRO), its partner for the development and commercialization of the PCA3 prostate cancer test, has confirmed today the beginning of a U.S. clinical study intended to secure U.S. regulatory approval of the PROGENSA(R) PCA3 assay, a new molecular test that may help determine the need for a repeat prostate biopsy.
Kaiser Permanente, one of America's leading health care providers and not-for-profit health plans, has been named one of INROADS' Top 10 Corporate Sponsors. The nation's largest non-profit source of salaried corporate internships, INROADS, Inc. develops diverse, skilled talent to become Corporate America's future business, science, technology, engineering and math (STEM) leaders.
The President and CEO of Three Rivers Pharmaceuticals, Donald J. Kerrish, RPh., stated, "The approval of Ribasphere™ marks a milestone in the treatment of HCV. Ribasphere™ is positioned to break down the economic barriers that have existed for the past decade in treating this chronic and potentially deadly disease." Traditionally the cost of treatment for HCV can range from $20,000 – $25,000 annually. "Our aim is to bring affordable medicine to all individuals infected with this dreadful disease." Mr. Kerrish continued.
New research findings may help scientists design drugs to treat a virus infection that causes potentially fatal brain swelling and paralysis in children.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Michael M Einstein, MD 2139 Silas Deane Hwy, Rocky Hill, CT 06067-2336 Ph: (860) 257-4131 | Michael M Einstein, MD 85 Seymour St, Suite 1000, Hartford, CT 06106-5501 Ph: (860) 246-2571 |
News Archive
DiagnoCure Inc. (TSX: CUR) announced that Gen-Probe, Inc. (NASDAQ: GPRO), its partner for the development and commercialization of the PCA3 prostate cancer test, has confirmed today the beginning of a U.S. clinical study intended to secure U.S. regulatory approval of the PROGENSA(R) PCA3 assay, a new molecular test that may help determine the need for a repeat prostate biopsy.
Kaiser Permanente, one of America's leading health care providers and not-for-profit health plans, has been named one of INROADS' Top 10 Corporate Sponsors. The nation's largest non-profit source of salaried corporate internships, INROADS, Inc. develops diverse, skilled talent to become Corporate America's future business, science, technology, engineering and math (STEM) leaders.
The President and CEO of Three Rivers Pharmaceuticals, Donald J. Kerrish, RPh., stated, "The approval of Ribasphere™ marks a milestone in the treatment of HCV. Ribasphere™ is positioned to break down the economic barriers that have existed for the past decade in treating this chronic and potentially deadly disease." Traditionally the cost of treatment for HCV can range from $20,000 – $25,000 annually. "Our aim is to bring affordable medicine to all individuals infected with this dreadful disease." Mr. Kerrish continued.
New research findings may help scientists design drugs to treat a virus infection that causes potentially fatal brain swelling and paralysis in children.
› Verified 4 days ago
Gagandeep Singh, MD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 114 Woodland St, Hartford, CT 06105 Phone: 860-714-7446 Fax: 860-714-1508 | |
Yixia Ye, MD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 31 Seymour St Ste 205, Hartford, CT 06106 Phone: 860-524-2610 | |
Andrew P Scatola, MD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 85 Jefferson Street, Hartford Hospital Cardiology Dept, Hartford, CT 06106 Phone: 860-972-1212 | |
Dr. David Jay Altszuler, MD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 85 Seymour St Ste 719, Hartford, CT 06106 Phone: 860-522-0604 Fax: 860-522-0604 | |
Dr. Nisha Dhanabalsamy, MBBS Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 80 Seymour St, Hartford, CT 06102 Phone: 860-972-0549 | |
Sindhuja Palle, MD Gastroenterology Medicare: Not Enrolled in Medicare Practice Location: 80 Seymour St, Hartford, CT 06106 Phone: 860-545-5000 | |
Dr. Jamie Matthew Roche, M.D. Gastroenterology Medicare: Not Enrolled in Medicare Practice Location: 80 Seymour St, Hartford, CT 06102 Phone: 860-545-3359 |